PET scans may reveal early if immunotherapy works for lung cancer

NCT ID NCT06833229

Recruiting now Knowledge-focused Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether special PET scans can predict early on if immunotherapy (with or without chemotherapy) is working in people with advanced non-small cell lung cancer. Researchers will scan 200 patients before treatment, then at 6 and 12 weeks, looking for signs that tell real tumor shrinkage apart from harmless inflammation. The goal is to avoid unnecessary treatments and side effects by spotting non-responders sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FDG-PET scan (imaging procedure)
What this could lead to: If successful, this could help doctors quickly tell if immunotherapy is working for lung cancer patients, avoiding ineffective treatments and side effects.
What could go wrong: This is an early observational study, not a treatment trial. The imaging method may not prove reliable enough to change standard care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)

Contacts and locations

Locations

Centre Antoine Lacassagne
RECRUITING

Nice, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.